Abbott Laboratories (ABT)
Pre-market:
| Previous close | 115.62 |
| Open | 116.21 |
| Bid | 0.00 x 1100 |
| Ask | 0.00 x 1000 |
| Day's range | 115.94 - 117.28 |
| 52-week range | 90.87 - 121.64 |
| Volume | |
| Avg. volume | 5,894,137 |
| Market cap | 202.037B |
| Beta (5Y monthly) | 0.72 |
| PE ratio (TTM) | 36.63 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.20 (1.89%) |
| Ex-dividend date | 15 Oct 2024 |
| 1y target est | N/A |
- PR Newswire
Abbott Advances Pulsed Field Ablation Clinical Studies and Launches New Technology to Support Advanced Cardiac Mapping
Abbott (NYSE: ABT) announced today it has achieved new major milestones to support the company's growing suite of pulsed field ablation (PFA) solutions in electrophysiology: early completion of enrollment in the VOLT-AF IDE Study supporting the Volt™ PFA System, and the launch of the FOCALFLEX trial to assess the company's TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ (SE), which will be used in the treatment of patients with paroxysmal atrial fibrillation. Together, these two studies repres
- PR Newswire
Abbott and the Big Ten Conference Tackle U.S. Blood Shortages with First-of-its-Kind, Nationwide Blood Donation Competition, 'The We Give Blood Drive'
Abbott (NYSE: ABT) is partnering with the Big Ten Conference and its 18-member university athletic departments to boost the U.S. blood supply through a blood donation competition. It will put rivalry and school spirit to the test as all of the schools compete to see who can donate the most blood, positively impacting lives across the country.
- PR Newswire
Abbott Hosts Conference Call for Third-Quarter Earnings
Abbott (NYSE: ABT) will announce its third-quarter 2024 financial results on Wednesday, Oct. 16, before the market opens.
